MRK - Merck & Co., Inc.
79.52 -0.06 (-0.08%)
After hours: 7:48PM EDT
| Previous close | 78.78 |
| Open | 79.24 |
| Bid | 78.82 x 800 |
| Ask | 79.52 x 1000 |
| Day's range | 78.90 - 80.02 |
| 52-week range | 65.25 - 92.64 |
| Volume | 7,335,805 |
| Avg. volume | 10,935,322 |
| Market cap | 200.868B |
| Beta (5Y monthly) | 0.49 |
| PE ratio (TTM) | 20.17 |
| EPS (TTM) | 3.94 |
| Earnings date | 31 Jul 2020 |
| Forward dividend & yield | 2.44 (3.10%) |
| Ex-dividend date | 12 Jun 2020 |
| 1y target est | 93.00 |
- Business Wire
Merck Announces New Analyses Showing Additional Safety and Efficacy Data for Investigational Islatravir in Combination with Doravirine in Adults with HIV-1 Infection
Merck Announces New Safety and Efficacy Data for Investigational Islatravir in Combination with Doravirine in Adults with HIV-1 Infection
- Stockopedia
Four clues to the quality of Merck amp; Co Inc (NYQ:MRK)
Warren Buffett makes it look so easy: find high-quality companies, wait for a fair price to buy, and then hold them... forever. The problem of course is that t...
- Simply Wall St.
How Many Merck & Co., Inc. (NYSE:MRK) Shares Do Institutions Own?
A look at the shareholders of Merck & Co., Inc. (NYSE:MRK) can tell us which group is most powerful. Institutions...
- Zacks
Why the Earnings Surprise Streak Could Continue for Merck (MRK)
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Business Wire
Merck Animal Health Completes Acquisition of U.S. Rights to SENTINEL® Brand of Combination Parasiticides for Companion Animals
Merck Animal Health Completes Acquisition of U.S. Rights to SENTINEL® Brand of Combination Parasiticides for Companion Animals
- Business Wire
Merck and Ridgeback Bio Announce Closing of Collaboration and Licensing Transaction
Merck and Ridgeback Bio Announce Closing of Collaboration and Licensing Transaction
- Business Wire
Merck to Hold Second-Quarter 2020 Sales and Earnings Conference Call on July 31
Merck to Hold Second-Quarter 2020 Sales and Earnings Conference Call on July 31
- Zacks
Merck (MRK) is a Top Dividend Stock Right Now: Should You Buy?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
- Zacks
Merck Gets FDA Nod for Keytruda Use in Colorectal Cancer
FDA approves Merck's (MRK) Keytruda for first-line treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer.
- Business Wire
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients With Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients With Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer
- Business Wire
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that is Not Curable by Surgery or Radiation
FDA Approves Merck’s KEYTRUDA® for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC).
- Business Wire
Merck Underscores Commitment to HIV with New Data Analyses to be Presented at AIDS 2020: Virtual
Merck Underscores Commitment to HIV with New Data Analyses to be Presented at AIDS 2020: Virtual
- Zacks
Merck (MRK) Outpaces Stock Market Gains: What You Should Know
Merck (MRK) closed the most recent trading day at $77.12, moving +0.48% from the previous trading session.
- Zacks
Merck's Pneumococcal Vaccine Meets Goal in Two Adult Studies
Merck's (MRK) development program on V114 comprises 16 studies, evaluating safety, tolerability and immunogenicity of V114 in a variety of patient populations.
- Business Wire
Merck Announces That V114, Its Investigational 15-valent Pneumococcal Conjugate Vaccine, Met Safety and Immunogenicity Objectives in Initial Phase 3 Studies in Adults
V114, Merck's Investigational 15-valent Pneumococcal Conjugate Vaccine, Met Safety and Immunogenicity Objectives in Initial Phase 3 Studies in Adults.
- Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Approved in China for Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Whose Tumors Express PD-L1 (CPS ≥10)
KEYTRUDA® Approved in China for Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- Zacks
Merck's Keytruda Gets Accelerated Approval for Solid Tumors
Merck's (MRK) sBLA seeking approval of Keytruda for advanced solid tumors, based on biomarker, regardless of tumor type, gets FDA's accelerated approval.
- Zacks
Merck (MRK) Dips More Than Broader Markets: What You Should Know
Merck (MRK) closed at $76.29 in the latest trading session, marking a -0.88% move from the prior day.
- Business Wire
Merck Animal Health Completes Acquisition of Quantified Ag®
Merck Animal Health Completes Acquisition of Quantified Ag®
- Zacks
Merck's Steglatro Non-Inferior in Cardiovascular Outcomes Study
Merck's (MRK) type 2 diabetes drug, Steglatro, achieves primary endpoint of non-inferiority in major adverse CV events compared to placebo in a late-stage cardiovascular outcomes study.
- Business Wire
FDA Approves Second Biomarker-Based Indication for Merck’s KEYTRUDA® (pembrolizumab), Regardless of Tumor Type
FDA Approves Second Biomarker-Based Indication for Merck’s KEYTRUDA (pembrolizumab), Regardless of Tumor Type
- Business Wire
Merck and Pfizer’s SGLT2 Inhibitor STEGLATROTM (ertugliflozin) Meets Primary Endpoint in VERTIS CV Trial for Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
Merck and Pfizer’s SGLT2 Inhibitor STEGLATRO Meets Primary Endpoint in VERTIS CV Trial for Patients with Type2 Diabetes and Atherosclerotic CV Disease
- Zacks
Merck's Gardasil Gets FDA Approval for Head and Neck Cancers
FDA grants accelerated approval for label expansion application of Merck's (MRK) human papillomavirus vaccine, Gardasil, to include oropharyngeal and other head and neck cancers.
